Anti‐angiogenic effects and mechanism of prazosin
- 6 December 2010
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 71 (9) , 976-984
Abstract
BACKGROUND Alpha1-adrenoceptors antagonists (doxazosin, terazosin, prazosin) are commonly prescribed for benign prostate hyperplasia and hypertension. Doxazosin and terazosin exhibit anti-angiogenic effects and apoptotic activities against multiple cell types and are potential preventive agents for prostate cancer. Prazosin induces apoptosis in three prostate cancer cell lines. We hypothesized that prazosin, a more potent alpha1-adrenoceptor antagonist with a distinct mechanism, exhibits anti-angiogenic activity. METHODS We examined the effect of prazosin on growth and tube formation of human umbilical vascular endothelial cells (HUVECs). We used flow cytometry to assess the effect of prazosin on cell cycle progression and Western blotting to assess its effect on the expression of various apoptotic proteins. RESULTS Prazosin inhibited the growth of HUVEC with an IC50 of 6.53 µM and suppressed tube formation in a dose-dependent manner. Unlike prostate cancer cells, prazosin did not arrest cell cycle progression at the G2/M checkpoint. We used rhodamine 123 staining to show that prazosin (20 µM) treatment induced a loss of mitochondrial membrane potential by 12 hr. Prazosin treatment of HUVECs resulted in reduced MCL-1 expression, increased Bad, and Bcl-xL expression, cytochrome c release, and induction of apoptosis via the intrinsic apoptosis pathway. Prazosin induced apoptosis in prostate cancer cells and normal HUVEC cells via different mechanisms. CONCLUSIONS These data suggest that prazosin exhibits anti-angiogenic activity and differentially modulates apoptotic pathways depending on the cell type. Prostate 71: 976–984, 2011.Keywords
This publication has 22 references indexed in Scilit:
- The α1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-κB signalling to induce breast cancer cell apoptosisEuropean Journal of Cancer, 2008
- Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort StudyJournal of Urology, 2007
- Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinicCancer Treatment Reviews, 2007
- Assessment of α1‐adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theoryBritish Journal of Clinical Pharmacology, 2006
- Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasionJournal of Cellular Biochemistry, 2004
- The role of α-blockers in the management of prostate cancerExpert Opinion on Pharmacotherapy, 2004
- Anoikis Induction by Quinazoline Based α1-Adrenoceptor Antagonists in Prostate Cancer Cells: Antagonistic Effect of Bcl-2Journal of Urology, 2003
- Identification of Apoptotic and Antiangiogenic Activities of Terazosin in Human Prostate Cancer and Endothelial CellsJournal of Urology, 2003
- Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasiaInternational Urology and Nephrology, 2001
- Carvedilol in the Treatment of Hypertension - A Review of the Clinical Data BaseScandinavian Cardiovascular Journal, 1998